IL2 and neoplasm: Of note, these two PRs were observed at the lowest T cell dose of 109, together with the plasma IL-2 in non-responders was as much as 10-fold lower compared to that in responders, the researchers drew a conclusion that adequate higher IL-2 in vivo plus a higher CAR-T cell dose could be beneficial to anti-tumor activity of anti-PSMA CAR-T cells, which is being tested in a redesign study.